 |
|
|
| |
Gastrointestinal (GI) Adverse Events With Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide
(D/C/F/TAF) Through Week 96: An AMBER Post Hoc Analysis
|
| |
| |
IDweek 2020 Oct 21-25 virtual
Reported by Jules Levin
Keith Dunn,1 Bryan Baugh,2 Nika Bejou,1,* Donghan Luo,3 Jennifer Campbell,1 David Anderson1
1Janssen Scientific Affairs, LLC, Titusville, NJ, USA; 2Janssen Research & Development, LLC, Raritan, NJ, USA; 3Janssen Research & Development, LLC, Titusville, NJ, USA.
|
| |
|
|
|
|
|
